AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit - ACI-7104.056 msn.com/en-us/health/other/...
AC Immune’s stock price has jumped by more than 20% after all patients in a trial of its Parkinson’s disease vaccine-like immunotherapy responded to the target antigen.
On Thursday (14 November), the Switzerland-based pharma company saw its stock rise by 26.9% from market close on 13 November to the 14 November high. The stock rose following the announcement of positive interim data from the Phase II (NCT06015841) VacSYn trial of its anti-alpha-synuclein (a-syn) active immunotherapy candidate ACI-7104.056.
Not only did the data show positive antibody responses against the target antigen at six weeks, but the responses were strongly boostable. a-syn is believed to be a key protein in the disease due to its high prevalence in patients with Parkinson's disease.
Treatment with ACI-7104.056 induced an increase in anti-a-syn antibodies on average 16-fold higher than the placebo background level after three immunisations.
CEO of AC Immune, Dr. Andrea Pfeifer, said: “The level of immunogenicity after only three months of treatment as well as the continued positive safety profile, reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of Parkinson’s disease.”
Gene therapy eases Parkinson’s symptoms by rewiring parts of the brain
Parkinson's disease is an autoimmune disease: An emerging viewpoint
Multiple mechanisms to clear a-synuclein with natural substances (in mice).
Interview of Daphne Bryan following the publication of her book: “Parkinson’s and the B1 therapy”.
